Alkem Laboratories Limited (NSE:ALKEM)

Market Cap	633.46B +0.2%
Revenue (ttm)	147.12B +13.5%
Net Income	23.02B +6.3%
EPS	192.51 +6.3%
Shares Out	119.57M
PE Ratio	27.52
Forward PE	26.86
Dividend	53.00 (1.00%)
Ex-Dividend Date	Aug 7, 2026

Volume	67,309
Open	5,340.00
Previous Close	5,301.50
Day's Range	5,283.00 - 5,358.50
52-Week Range	4,716.20 - 5,933.50
Beta	0.27
Analysts	Hold
Price Target	5,956.45 (+12.43%)
Earnings Date	May 28, 2026

About Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, r...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 18,785
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALKEM

Financial Performance

In fiscal year 2026, Alkem Laboratories's revenue was 147.12 billion, an increase of 13.48% compared to the previous year's 129.65 billion. Earnings were 23.02 billion, an increase of 6.30%.

Analyst Summary

According to 20 analysts, the average rating for ALKEM stock is "Hold." The 12-month stock price target is ₹5,956, which is an increase of 12.43% from the latest price.

Price Target

₹5,956

(12.43% upside)

Analyst Consensus: Hold